

SECTION 1 – INFORMATION ON THE MEMBER				
Member name:		Group number:		Certificate number:
Address (No. / Street / Apt.):				
City :	Province :		Postal Code :	
Phone number :		E-mail address :		
Employer name / Policy holder: :		Group / Division number:		
SECTION 2 – INFORMATION ON THE PATIENT				
Patient name:				
Patient Date of Birth (YYYY/MM/DD):		Relationship to member:		
Have you applied for coverage with a provincial program? ☐ YES ☐ NO				
Has your application for coverage with the provincial program for this drug or supply been approved? ☐ YES ☐ NO				
If you have applied for coverage with a provincial program, please provide us with a copy of the refusal or acceptance letter.				
Are you enrolled in a drug manufacturer's patient assistance program? ☐ YES ☐ NO				
If yes, please provide your patient assistance program identification number: _____				
SECTION 3 - AUTHORIZATION TO SHARE PERSONAL INFORMATION				
I authorize any health professional (doctor, pharmacist, dentist), any person (service provider), any other insurance company, any public or private health institution, any government agency in relation to health or social services, to disclose and exchange requested information by the insurer or AGA Benefits Solutions, necessary for the evaluation of my request for prior authorization for that drug.				
Patient signature:		Date:		
Signature of the subscriber when patient is a minor:		Date:		
SECTION 4 - DRUG COVERED BY THE APPLICATION				
Drug Name:				
Dosage:				
Pharmaceutical Form:		Content / Strength:		
Anticipated duration of treatment:	From (YYYY/MM/DD) :	To (YYYY/MM/DD) :		
Diagnosis:		Initial date of diagnosis (YYYY-MM-DD):		
Medication will be administered at the following location:				
☐ Home	☐ Health and social service center	☐ Long-term care center	☐ Private clinic	
☐ Hospital - internal patient	☐ Hospital - external patient	☐ Elsewhere. Specify : _____		
If the treatment is not administered at home, please provide the following information:				
Name of the location where the drug will be administered:			Telephone:	
Address (No. / Street / Apt.):		City :	Province:	Postal Code :
SECTION 5 - TYPE OF APPLICATION				
☐ Initial request	☐ Continued treatment		☐ Modification of treatment	

SECTION 6- SUMMARY OF PREVIOUS TRIALS OR CONTRAINDICATIONS

Please provide a list of medicines and/or treatments used to date to control this condition:

Name of drug/treatment currently or previously prescribed	Content - strength / Dosage	Trial Period		Reason for Discontinuation
		From (YYYY-MM-DD)	To (YYYY-MM-DD)	
				☐ Allergy ☐ Intolerance ☐ Ineffective ☐ Relapse ☐ Other Specify:
				☐ Allergy ☐ Intolerance ☐ Ineffective ☐ Relapse ☐ Other Specify:
				☐ Allergy ☐ Intolerance ☐ Ineffective ☐ Relapse ☐ Other Specify:
				☐ Allergy ☐ Intolerance ☐ Ineffective ☐ Relapse ☐ Other Specify:

SECTION 7 - CLINICAL INFORMATION SPECIFIC TO THIS APPLICATION

DIAGNOSIS

- ☐ Weight Management
☐ Metabolic dysfunction-Associated Steatohepatitis (MASH)
☐ Risk of Myocardial Infarction
☐ Other. Specify: _____

WEIGHT MANAGEMENT

Please provide the following pre-treatment information as well as the date on which they were obtained :

Weight Initial assessment : _____ kg/lbs Date (YYYY/MM/DD) : _____
Height Initial assessment : _____ cm/in Date (YYYY/MM/DD) : _____
Waist circumference Initial assessment : _____ cm/in Date (YYYY/MM/DD) : _____
BMI Initial assessment : _____ kg/m² Date (YYYY/MM/DD) : _____

I confirm I have verified the above measurements: ☐ Yes ☐ No Signature: _____

Will the drug be used in combination with other GLP-1 agonists? ☐ Yes ☐ No

Is the patient actively involved in :

- ☐ A dietary/behaviour modification program for weight loss
☐ A fitness exercise regimen

Has the patient failed a previous weight management intervention? ☐ Yes ☐ No

Patient's sex at birth*: ☐ Female ☐ Male ☐ Intersex

Is the patient of South Asian, Southeast Asian or East Asian ethnicity*? ☐ Yes ☐ No

**These questions are optional. Canadian Adult Obesity Clinical Practice Guidelines recommend different measured waist circumference and/or BMI cut offs for females and males, and for those of South-, Southeast- or East Asian ethnicity.*

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

Does the patient have moderate to advanced liver fibrosis (consistent with stage F2 or F3)? ☐ Yes ☐ No

Was the diagnosis confirmed by a specialist with expertise in the management of MASH (e.g. gastroenterologist or hepatologist)? ☐ Yes ☐ No

Please indicate which test was performed to verify MASH diagnosis:

- ☐ Liver biopsy Date (YYYY/MM/DD) : _____
☐ Vibration-controlled transient elastography (VCTE, e.g. Fibroscan) Date (YYYY/MM/DD) : _____
☐ Magnetic Resonance Elastography (MRE) Date (YYYY/MM/DD) : _____
☐ Shear wave elastography (SWE) Date (YYYY/MM/DD) : _____

Continue to page 3

Does the patient have any documented cause of chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD) (e.g. alcoholic steatohepatitis, acute fatty liver, autoimmune hepatitis, Hepatitis A, B or C, hemochromatosis, drug-induced liver disease)? ☐ Yes ☐ No

Does the patient have a NAS ≥ 4 with steatosis > 1 , ballooning > 1 , and lobular inflammation > 1 ? ☐ Yes ☐ No

Does the patient have decompensated cirrhosis? ☐ Yes ☐ No

Does the patient have significant alcohol consumption (>20 g per day for women and >30 g per day for men)? ☐ Yes ☐ No

Does the patient have overweight or obesity? ☐ Yes ☐ No

Will the drug be used in conjunction with a reduced-calorie diet, increased physical activity, and behavioural modifications? ☐ Yes ☐ No

Will the drug be used in combination with other GLP-1 agonists? ☐ Yes ☐ No

RISK OF MYOCARDIAL INFARCTION

Does the patient have established cardiovascular disease? ☐ Yes ☐ No

☐ If yes, check all that apply: ☐ Acute coronary syndrome (ACS) ☐ Coronary artery disease documented using angiography

☐ Stable or unstable angina ☐ Stroke ☐ Transient ischemic attack ☐ Documented carotid disease

☐ Coronary or other arterial revascularization (coronary artery bypass graft surgery, femoral popliteal bypass graft surgery, etc.) ☐ Peripheral artery disease

☐ Abdominal aortic aneurysm ☐ Myocardial infarction (MI) ☒ Date of the event:: _____

☐ Other. Specify: _____

Does the patient have diabetes? ☐ Yes ☐ No ☒ If yes, indicate which type: ☐ Type 1 ☐ Type 2

Patient's weight management history:

Has the patient been following a reduced calorie diet or other dietary pattern that is associated with weight reduction for at least 6 months in the past 24 months? ☐ Yes ☐ No

If yes, specify the diet(s) and dates:

Diet(s): _____

From _____ to _____

Has the patient engaged in an increased level of physical activity for chronic weight management for at least 6 months in the past 24 months? ☐ Yes ☐ No

If yes, specify the physical activities and dates:

Activities: _____

From _____ to _____

Has the patient participated in behavioural interventions for chronic weight management for at least 6 months in the past 24 months? ☐ Yes ☐ No

If yes, specify the name and specialty of the provider or healthcare professional, or the name of the program: _____

From _____ to _____

If you answered "no" to any of the above questions, please indicate why: _____

Check all adiposity-related complications that apply:

☐ Prediabetes

☐ Impaired fasting glucose

☐ Impaired glucose tolerance

☐ A1C 6.0 to 6.4%

or ☐ Type 2 diabetes

Provide related test results, scores and information:

A1C: _____% (Date: _____)

If prediabetes, also provide:

Fasting glucose: _____ mmol/L (Date: _____)

2-hour glucose tolerance: _____ mmol/L (Date: _____)

☐ Sleep Apnea	Apnea Hypopnea Index: _____ Requires a CPAP: ☐ Yes ☐ No
☐ Cardiovascular risk or ☐ Heart disease ↳ ☐ Angina pectoris ☐ Stent placement ☐ Coronary artery bypass ☐ Prior myocardial infarction ☐ Stroke ☐ Symptomatic peripheral vascular disease ☐ Heart failure	Blood pressure: _____ mm Hg (Date: _____) HDL-C: _____ mmol/L (Date: _____) Total cholesterol: _____ mmol/L (Date: _____) Is the patient using antihypertensive medication? ☐ Yes ☐ No ↳ If yes, specify drug name(s) and dosage(s) : _____ <u>If cardiovascular risk, also provide:</u> Framingham risk score: _____ % (Date: _____)
☐ Borderline hypertension or ☐ Hypertension	Blood pressure: _____ mmHg (Date: _____) Is the patient using antihypertensive medication? ☐ Yes ☐ No ↳ If yes, specify drug name(s) and dosage(s): _____
☐ Impaired function or mobility	Number of flights of stairs the patient is able to manage: _____ Is the patient using pain medication? ☐ Yes ☐ No ↳ If yes, specify drug name(s) and dosage(s): _____ _____ Does the patient require walking aids? ☐ Yes ☐ No ↳ If yes, specify walking aids required: _____ _____
☐ Elevated liver function or ☐ NAFLD/MASLD or ☐ NASH/MASH	ALT: _____ U/L (Date: _____) <u>If NAFLD/MASLD or NASH/MASH, also provide:</u> FIB-4: _____ U/L (Date: _____) Fasting insulin (optional): _____ ☐ uIU/mL ☐ pmol/L
☐ Esophagitis	<u>Check all that apply:</u> ☐ Two or more episodes of GERD per week ☐ Severe symptoms ☐ Esophagitis on endoscopy Does the patient require daily proton pump inhibitor (PPI) at standard dose or higher for longer than 8 weeks? ☐ Yes ☐ No ↳ If yes, specify drug name(s) and dosage(s): _____ _____ _____

☐ Polycystic ovary syndrome (PCOS) <u>or</u> ☐ Male sexual dysfunction	Blood pressure: _____ mm Hg (Date: _____) HDL-C: _____ mmol/L (Date: _____) Triglycerides: _____ mmol/L (Date: _____) Non-HDL-C: _____ mmol/L (Date: _____) A1C: _____ % (Date: _____) Fasting glucose: _____ mmol/L (Date: _____) 2-hour glucose tolerance: _____ mmol/L (Date: _____) Is the patient using antihypertensive drug? ☐ Yes ☐ No ▶ If yes, specify drug name(s) and dosage(s): _____ _____ <u>If polycystic ovary syndrome (PCOS), also provide:</u> <u>Ovulatory function:</u> ☐ Normal ovulatory cycles ☐ Oligo-ovulatory cycles ☐ Anovulation <u>If male sexual dysfunction, also provide:</u> Is the patient using ED medications? ☐ Yes ☐ No Total testosterone: _____ mmol/L (Date: _____)
---	---

SECTION 8 - CLINICAL INFORMATION REGARDING RENEWAL

Has the patient lost at least 5% of their initial body weight? ☐ Yes ☐ No

Date of initial evaluation (pretreatment): _____ Date of most recent evaluation: _____

Items measured:	Initial evaluation (pretreatment):	Most recent evaluation:
Weight:	_____ kg/lbs	_____ kg/lbs
Height (in cm):	_____ cm	_____ cm
BMI:	_____ kg/m2	_____ kg/m2
Waist circumference (in cm):	_____ cm	_____ cm

Indicate test results, scores and information showing improvement in the patient's adiposity-related complications:

Items measured:	Initial evaluation (pretreatment):	Most recent evaluation:
A1C (%):		
Fasting glucose (mmol/L):		
2-hour glucose tolerance (mmol/L):		
Blood pressure (mm Hg):		
Antihypertensive drug name(s) and dosage(s):		
HDL-C (mmol/L):		
Total cholesterol (mmol/L):		
Triglycerides (mmol/L):		
Non-HDL-C (mmol/L):		

Continue to page 6

Framingham risk score (%):		
Patient had new myocardial infarction or stroke:	N/A	☐ Yes ☐ No
Patient had new cardiovascular-related hospitalization:	N/A	☐ Yes ☐ No
Patient had new coronary revascularization:	N/A	☐ Yes ☐ No
Number of flights of stairs the patient is able to manage:		
Improvement in knee functionality (i.e., speed and walk distance):	N/A	☐ Yes ☐ No
Uses walking aids:	☐ Yes ☐ No	☐ Yes ☐ No
Pain medication name(s) and dosage(s):		
ALT (U/L):		
Fasting insulin (☐ uUI/mL ☐ pmol/L) :		
Apnea Hypopnea Index:		
Requires a CPAP:	☐ Yes ☐ No	☐ Yes ☐ No
Improved esophagitis symptoms (specify):		
Proton pump inhibitor name(s), dosage(s) and duration of use:		
Ovulatory function:	☐ Normal ovulatory cycles ☐ Oligo-ovulatory cycles ☐ Anovulation	☐ Normal ovulatory cycles ☐ Oligo-ovulatory cycles ☐ Anovulation
Total testosterone (nmol/L):		
Decrease of erectile dysfunction incidents:	N/A	☐ Yes ☐ No
ED medication name(s), dosage(s) and frequency of use:		
Metabolic dysfunction-Associated Steatohepatitis (MASH)	N/A	☐ Positive clinical response ☐ MASH/NASH resolution AND no worsening of fibrosis ☐ No worsening of MASH/NASH AND improvement in fibrosis by ≥ 1 stage
Presence of decompensated cirrhosis	N/A	☐ Yes ☐ No
FIB-4 :		

Has the patient been on **Wegovy** 2.4 mg weekly or maximum tolerated dose of 1.7 mg weekly for at least 12 weeks?

☐ Yes ☐ No

Has the patient been on **Saxenda** 3 mg weekly or maximum tolerated dose of 2.4 mg weekly for at least 12 weeks?

☐ Yes ☐ No

Has the patient been on **Zepbound** 5 mg weekly or higher for at least 12 weeks? ☐ Yes ☐ No

If you answered "no" to any of the above questions, specify how many weeks the patient has been on that dose: _____ weeks

Will the drug be used in combination with other GLP-1 agonists? ☐ Yes ☐ No

Will the drug be used in conjunction with a reduced-calorie diet, increased physical activity, and behavioural modifications?

☐ Yes ☐ No

SECTION 9– ADDITIONAL INFORMATION (optional)

SECTION 10 – SIGNATURE OF AUTHORIZED PRESCRIBER

Print name of authorized prescriber:	Specialty of the physician:	
Signature of authorized prescriber:	License Number:	Date :

SECTION 11 - IMPORTANT PATIENT INFORMATION

Fees may be charged to complete this form, it is the patient's responsibility to pay them.
Ensure all required sections of the form have been completed and signed before returning it.
Attach any additional documents required on this form.
Your request may be delayed if we do not have all the necessary information.
The drug will be eligible only if it meets the criteria established by the insurer.

HOW TO RETURN THE FORM

Submit a claim through the **members portal**
Claim type *Prior authorization drugs*

By mail : AGA Benefit Solutions
3500 de Maisonneuve Blvd. W, suite 2200
Westmount (QC) H3Z 3C1